"The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfiel"...
- Patient Information:
Details with Side Effects
Aranesp overdosage can cause hemoglobin levels above the desired level, which should be managed with discontinuation or reduction of Aranesp dosage and/or with phlebotomy, as clinically indicated [see Pharmacodynamics]. Cases of severe hypertension have been observed following overdose with ESAs [see WARNINGS AND PRECAUTIONS].
Aranesp is contraindicated in patients with:
- Uncontrolled hypertension [see WARNINGS AND PRECAUTIONS].
- Pure red cell aplasia (PRCA) that begins after treatment with Aranesp or other erythropoietin protein drugs [see WARNINGS AND PRECAUTIONS].
- Serious allergic reactions to Aranesp [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 1/27/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Aranesp Information
Aranesp - User Reviews
Aranesp User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.